Market Overview

Aegis Capital Downgrades Recro Pharma, Says Investors Should Be Cautious


Aegis Capital downgraded Recro Pharma Inc (NASDAQ: REPH) Tuesday from Buy to Hold and did not set a price target.

Analyst Yi Chen noted that “Recro Pharma started a Phase 2 clinical trial of Dex-IN, its proprietary intranasal formulation of dexmedetomidine, in late October 2014 in the post-operative Day 1 setting for pain management following bunionectomy surgery.”

Regarding the current phase, Chen commented that “though theoretically the Day 1 setting should produce better efficacy than the Day 0 setting, investors ought to be cautious at this point, in our view.”

Chen cited a the previous Post Op Day 0 Phase 2 trial in September 2014 in which 95 received Dex-IN “with no serious adverse events, though four patients...discontinued due to symptomatic hypotension and one subject [discontinued] due to fever.”

With $23.9 million in cash at the end of September 30, 2014, Chen concluded “that the company shares currently trade at its cash value with a negative enterprise value. If the Day 1 Phase 2 trial reports positive data, the firm may need to raise additional capital by end-2015 for a Phase 3 trial.”

Recro Pharma Inc. recently traded at $2.77, down 4.57 percent.

Latest Ratings for REPH

May 2020OppenheimerMaintainsOutperform
Mar 2020Stephens & Co.MaintainsOverweight
Nov 2019Stephens & Co.MaintainsOverweight

View More Analyst Ratings for REPH
View the Latest Analyst Ratings


Related Articles (REPH)

View Comments and Join the Discussion!

Posted-In: Aegis Capital yi chenAnalyst Color Downgrades Analyst Ratings

Latest Ratings

NXPIWells FargoMaintains200.0
ANTMCowen & Co.Maintains360.0
BOOTWells FargoMaintains68.0
CREEDeutsche BankMaintains100.0
FBDeutsche BankMaintains350.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at